Developer docs
API playgroundTry for free, no card

Search company profiles

Miimansa

Full company profile

uuid006e91h

Namestring
Miimansa
Legal namestring
Miimansa AI
Websiteurl
miimansa.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Miimansa AI is an Indian health-tech company that builds AI-powered software for transforming unstructured clinical data into standardized, analytics-ready datasets. The company's flagship platform, BridgeCloud™, operates as a four-stage pipeline: PrivacyBridgeAI handles locale-aware PHI de-identification; MedBridgeAI structures and normalizes clinical texts into OMOP/CDM, FHIR, and SNOMED-compliant datasets; KnowledgeBridgeAI delivers real-time evidence retrieval and conversational AI over clinical literature; and TrialBridgeAI (in development) supports patient cohort discovery and clinical trial feasibility. The platform is powered by a patent-pending proprietary retrieval framework called AIPR (Anchor-Indexed Passage Retrieval), which combines domain-adapted embeddings, key-phrase indexing, and hierarchical semantic search for clinical text. Miimansa also offers a MedBridgeAI Copilot add-on to accelerate OMOP CDM 5.4 transformation workflows.

The company primarily serves enterprise healthcare and life sciences buyers, including hospitals, academic medical centers, clinical research organizations (CROs), pharmaceutical companies, and insurance firms. Its go-to-market is enterprise sales-led with a 'Request a Demo' conversion model, supplemented by strategic channel partnerships — most notably a multi-year partnership with Emmes Group for global CRO distribution. Revenue is generated through SaaS subscriptions and managed services, though pricing is quote-based and not publicly disclosed. Miimansa's defensibility rests on locale-specific AI models tuned for Indian clinical data, research collaborations with IIT Kanpur, SGPGIMS, and ICMR-NIRDHDS, and a leadership team with Stanford and IIT credentials. The company has 1-10 employees, is privately held, and has not disclosed any institutional funding rounds.

Short descriptiontext

Miimansa AI is an Indian health-tech company that builds AI-powered software to transform unstructured clinical data into standardized, OMOP-compliant datasets for hospitals, CROs, and pharma via its BridgeCloud platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical data transformation, healthcare AI software, privacy-preserving analytics, structured electronic health records, clinical research data platforms
Industry4 codes
PRIMARYHLACABAJ
Terminology Services & Semantic Interoperability (SNOMED/LOINC/RxNorm mapping)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Health Services8000
Product category
Healthcare AI Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1MedBridgeAI SaaS Subscription
TypeSubscription Recurring
Description

Cloud-native, privacy-safe AI delivered as a service for OMOP CDM transformation. Customers avoid infrastructure build-out while maintaining strong data governance. Operates on subscription basis with zero compute-hardware investment required from clients.

miimansa.com
2BridgeCloud™ Platform Services
TypeManaged Services
Description

Integrated platform providing end-to-end de-identification pipeline, standardization, and AI-driven clinical data transformation as managed services. Includes automated compliance reports, interactive dashboards, and API access.

miimansa.com
3TrialBridgeAI (Under Development)
TypeSubscription Recurring
Description

Patient matching and cohort discovery capabilities currently under development with clinical research partners for joint pilot studies.

miimansa.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Miimansa develops and sells BridgeCloud, an AI-powered clinical data transformation platform that ingests unstructured patient notes from electronic health records (EHRs) and converts them into structured, de-identified, standardized datasets ready for research, analytics, and clinical trials. The platform bundles privacy-preserving de-identification, clinical NLP coding to ICD-10/SNOMED/RxNorm/LOINC, knowledge graph construction, and a conversational AI copilot, sold to healthcare providers, CROs, pharmaceutical/life sciences companies, and insurance payers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • 60-70% reduction in clinical data curation time
+11 more records
Product overview1 text field

Miimansa offers BridgeCloud™, an integrated AI-powered cloud platform for clinical data transformation. The platform comprises four modular products that work together in a pipeline architecture: PrivacyBridgeAI (Stage 1 - Privacy/De-identification) securely de-identifies raw clinical records with locale-aware precision; MedBridgeAI (Stage 2 - Structure) transforms safe data into OMOP/CDM-normalized structured datasets; KnowledgeBridgeAI (Stage 3 - Insight) mines structured data for real-time knowledge retrieval and conversational AI; and TrialBridgeAI (Stage 4 - Action) enables intelligent patient matching and cohort discovery for clinical research. An optional MedBridgeAI Copilot add-on accelerates OMOP CDM 5.4 transformation workflows. The platform is powered by proprietary patent-pending AIPR (Anchor-Indexed Passage Retrieval) technology for semantic search and retrieval-augmented generation.

Product and service1 record
1BridgeCloud Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-08-05
Description

Multi-year strategic partnership with Emmes Group, a leading specialty tech-enabled global CRO with over 45 years of experience. Joint development of advanced clinical data management solutions, integration of AI technologies into clinical trial workflows, and AI-powered clinical document authoring. The 'Innovation-to-Impact' model positions Miimansa as the innovation engine and Emmes as the impact driver.

2IIT Kanpur (Indian Institute of Technology Kanpur)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration focused on advanced AI and machine learning technologies for healthcare applications. Joint research on PHI de-identification systems, natural language processing for clinical text, AI model development and validation, and Digital Public Goods for AI in Health.

miimansa.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with SGPGIMS for clinical validation and real-world testing of AI systems. Joint work on AI-powered clinical data de-identification and data warehousing, participation in AI committee, and real-world validation of MedBridgeAI implementation in the Nephrology department.

4ICMR-NIRDHDS (Indian Council of Medical Research - National Institute for Research in Digital Health and Data Science)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership on healthcare standards and ethical frameworks. Joint initiatives include ethical AI framework collaboration, ethics committee participation, and research methodology best practices for responsible AI in healthcare.

miimansa.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Deep 6 AI
TypeDirect peer
Description

AI-powered patient matching and cohort discovery platform for clinical trials. Directly comparable to Miimansa's TrialBridgeAI in translating eligibility criteria against EHR data to accelerate trial recruitment.

TypeDirect peer
Description

Healthcare-focused NLP company offering Spark NLP for clinical and biomedical text, including de-identification, entity extraction, and terminology mapping. Closest comparable in clinical text transformation with an established customer base across pharma and providers.

TypeBroad incumbent
Description

Amazon's cloud-based clinical NLP service for entity extraction, de-identification, and medical text analysis. Hyperscaler incumbent that competes at the baseline feature set of Miimansa's PrivacyBridgeAI and MedBridgeAI.

4Mendel AI
TypeEmerging player
Description

Clinical NLP company that transforms unstructured medical records into structured data for healthcare and life sciences use cases. Comparable in clinical text structuring, though with broader US enterprise focus versus Miimansa's Indian specialization.

TypeBroad incumbent
Description

Largest global CRO and real-world evidence provider offering comprehensive clinical research, data, and technology services. Comparable as a customer/competitor in the CRO + clinical data analytics space Miimansa targets through Emmes partnership.

TypeBroad incumbent
Description

Google's healthcare data platform supporting FHIR, DICOM, and HL7v2 interoperability. Comparable to Miimansa's FHIR/SNOMED integration capabilities but as part of a much broader cloud ecosystem rather than a focused clinical AI stack.

TypeDirect peer
Description

Oncology-focused clinical data platform (acquired by Roche) that structures EHR data for real-world evidence and research. Directly comparable to MedBridgeAI's oncology use cases and OMOP-based clinical data transformation.

TypeDirect peer
Description

Global health research network leveraging real-world data and clinical trial analytics. Comparable to MedBridgeAI/KnowledgeBridgeAI in enabling federated queries across standardized clinical datasets for pharma-sponsored research.

TypeBroad incumbent
Description

Microsoft's healthcare-focused cloud offering with FHIR-based data aggregation, AI services, and clinical insights. Broad incumbent comparable to Miimansa's interoperability and AI-driven insights functionality but at hyperscaler scale.

TypeDirect peer
Description

Healthcare data connectivity company specializing in privacy-preserving record linkage and de-identification of patient data. Highly comparable to Miimansa's PrivacyBridgeAI and data exchange functionality across the clinical research value chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Miimansa

Healthcare AI Softwaremiimansa.com

Miimansa AI is an Indian health-tech company that builds AI-powered software to transform unstructured clinical data into standardized, OMOP-compliant datasets for hospitals, CROs, and pharma via its BridgeCloud platform.

What Miimansa does

Miimansa AI is an Indian health-tech company that builds AI-powered software for transforming unstructured clinical data into standardized, analytics-ready datasets. The company's flagship platform, BridgeCloud™, operates as a four-stage pipeline: PrivacyBridgeAI handles locale-aware PHI de-identification; MedBridgeAI structures and normalizes clinical texts into OMOP/CDM, FHIR, and SNOMED-compliant datasets; KnowledgeBridgeAI delivers real-time evidence retrieval and conversational AI over clinical literature; and TrialBridgeAI (in development) supports patient cohort discovery and clinical trial feasibility. The platform is powered by a patent-pending proprietary retrieval framework called AIPR (Anchor-Indexed Passage Retrieval), which combines domain-adapted embeddings, key-phrase indexing, and hierarchical semantic search for clinical text. Miimansa also offers a MedBridgeAI Copilot add-on to accelerate OMOP CDM 5.4 transformation workflows.

The company primarily serves enterprise healthcare and life sciences buyers, including hospitals, academic medical centers, clinical research organizations (CROs), pharmaceutical companies, and insurance firms. Its go-to-market is enterprise sales-led with a 'Request a Demo' conversion model, supplemented by strategic channel partnerships — most notably a multi-year partnership with Emmes Group for global CRO distribution. Revenue is generated through SaaS subscriptions and managed services, though pricing is quote-based and not publicly disclosed. Miimansa's defensibility rests on locale-specific AI models tuned for Indian clinical data, research collaborations with IIT Kanpur, SGPGIMS, and ICMR-NIRDHDS, and a leadership team with Stanford and IIT credentials. The company has 1-10 employees, is privately held, and has not disclosed any institutional funding rounds.

Miimansa firmographics

Firmographics
Name
Miimansa
Legal name
Miimansa AI
Website
https://miimansa.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Miimansa AI is an Indian health-tech company that builds AI-powered software to transform unstructured clinical data into standardized, OMOP-compliant datasets for hospitals, CROs, and pharma via its BridgeCloud platform.
Ownership category
akta.pro rank

Miimansa industry classification

Industry
Product category
Healthcare AI Software
NAICS
Software Publishers (513210)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLACABAJ
Terminology Services & Semantic Interoperability (SNOMED/LOINC/RxNorm mapping)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Clinical data transformation
  • Healthcare AI software
  • Privacy-preserving analytics
  • Structured electronic health records
  • Clinical research data platforms

Miimansa business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. MedBridgeAI SaaS Subscription: Cloud-native, privacy-safe AI delivered as a service for OMOP CDM transformation. Customers avoid infrastructure build-out while maintaining strong data governance. Operates on subscription basis with zero compute-hardware investment required from clients.
  2. BridgeCloud™ Platform Services: Integrated platform providing end-to-end de-identification pipeline, standardization, and AI-driven clinical data transformation as managed services. Includes automated compliance reports, interactive dashboards, and API access.
  3. TrialBridgeAI (Under Development): Patient matching and cohort discovery capabilities currently under development with clinical research partners for joint pilot studies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Miimansa product offering

Product offering

Core offering

Miimansa develops and sells BridgeCloud, an AI-powered clinical data transformation platform that ingests unstructured patient notes from electronic health records (EHRs) and converts them into structured, de-identified, standardized datasets ready for research, analytics, and clinical trials. The platform bundles privacy-preserving de-identification, clinical NLP coding to ICD-10/SNOMED/RxNorm/LOINC, knowledge graph construction, and a conversational AI copilot, sold to healthcare providers, CROs, pharmaceutical/life sciences companies, and insurance payers.

Product overview

Miimansa offers BridgeCloud™, an integrated AI-powered cloud platform for clinical data transformation. The platform comprises four modular products that work together in a pipeline architecture: PrivacyBridgeAI (Stage 1 - Privacy/De-identification) securely de-identifies raw clinical records with locale-aware precision; MedBridgeAI (Stage 2 - Structure) transforms safe data into OMOP/CDM-normalized structured datasets; KnowledgeBridgeAI (Stage 3 - Insight) mines structured data for real-time knowledge retrieval and conversational AI; and TrialBridgeAI (Stage 4 - Action) enables intelligent patient matching and cohort discovery for clinical research. An optional MedBridgeAI Copilot add-on accelerates OMOP CDM 5.4 transformation workflows. The platform is powered by proprietary patent-pending AIPR (Anchor-Indexed Passage Retrieval) technology for semantic search and retrieval-augmented generation.

Differentiator

Problem solved

Functional benefit

Products and services

  • BridgeCloud Platform

Quantifiable outcome

  • 60-70% reduction in clinical data curation time
  • +11 more outcomes

Companies that use Miimansa

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Miimansa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

Miimansa partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and strategic.

  • Emmes GroupflagshipStrategic or Co-development Partner · 5 August 2024Multi-year strategic partnership with Emmes Group, a leading specialty tech-enabled global CRO with over 45 years of experience. Joint development of advanced clinical data management solutions, integration of AI technologies into clinical trial workflows, and AI-powered clinical document authoring. The 'Innovation-to-Impact' model positions Miimansa as the innovation engine and Emmes as the impact driver.
  • IIT Kanpur (Indian Institute of Technology Kanpur)coreStrategic or Co-development PartnerResearch collaboration focused on advanced AI and machine learning technologies for healthcare applications. Joint research on PHI de-identification systems, natural language processing for clinical text, AI model development and validation, and Digital Public Goods for AI in Health.
  • SGPGIMS (Sanjay Gandhi Postgraduate Institute of Medical Sciences)coreStrategic or Co-development PartnerCollaboration with SGPGIMS for clinical validation and real-world testing of AI systems. Joint work on AI-powered clinical data de-identification and data warehousing, participation in AI committee, and real-world validation of MedBridgeAI implementation in the Nephrology department.
  • ICMR-NIRDHDS (Indian Council of Medical Research - National Institute for Research in Digital Health and Data Science)strategicStrategic or Co-development PartnerPartnership on healthcare standards and ethical frameworks. Joint initiatives include ethical AI framework collaboration, ethics committee participation, and research methodology best practices for responsible AI in healthcare.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Miimansa competitors and assessment

Company assessment

Direct peers

  • Deep 6 AI: AI-powered patient matching and cohort discovery platform for clinical trials. Directly comparable to Miimansa's TrialBridgeAI in translating eligibility criteria against EHR data to accelerate trial recruitment.
  • John Snow Labs: Healthcare-focused NLP company offering Spark NLP for clinical and biomedical text, including de-identification, entity extraction, and terminology mapping. Closest comparable in clinical text transformation with an established customer base across pharma and providers.
  • Flatiron Health: Oncology-focused clinical data platform (acquired by Roche) that structures EHR data for real-world evidence and research. Directly comparable to MedBridgeAI's oncology use cases and OMOP-based clinical data transformation.
  • TriNetX: Global health research network leveraging real-world data and clinical trial analytics. Comparable to MedBridgeAI/KnowledgeBridgeAI in enabling federated queries across standardized clinical datasets for pharma-sponsored research.
  • Datavant: Healthcare data connectivity company specializing in privacy-preserving record linkage and de-identification of patient data. Highly comparable to Miimansa's PrivacyBridgeAI and data exchange functionality across the clinical research value chain.

Broad incumbents

  • AWS Comprehend Medical: Amazon's cloud-based clinical NLP service for entity extraction, de-identification, and medical text analysis. Hyperscaler incumbent that competes at the baseline feature set of Miimansa's PrivacyBridgeAI and MedBridgeAI.
  • IQVIA: Largest global CRO and real-world evidence provider offering comprehensive clinical research, data, and technology services. Comparable as a customer/competitor in the CRO + clinical data analytics space Miimansa targets through Emmes partnership.
  • Google Cloud Healthcare API: Google's healthcare data platform supporting FHIR, DICOM, and HL7v2 interoperability. Comparable to Miimansa's FHIR/SNOMED integration capabilities but as part of a much broader cloud ecosystem rather than a focused clinical AI stack.
  • Microsoft Cloud for Healthcare: Microsoft's healthcare-focused cloud offering with FHIR-based data aggregation, AI services, and clinical insights. Broad incumbent comparable to Miimansa's interoperability and AI-driven insights functionality but at hyperscaler scale.

Emerging players

  • Mendel AI: Clinical NLP company that transforms unstructured medical records into structured data for healthcare and life sciences use cases. Comparable in clinical text structuring, though with broader US enterprise focus versus Miimansa's Indian specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Miimansa social profiles

Digital presence

Miimansa compliance and trust

Trust signal

Compliance4 records

Miimansa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Miimansa leadership team

Management profile

Number of profiles

Profiles5 records

Miimansa funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Miimansa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miimansa

What does Miimansa do?

Miimansa develops and sells BridgeCloud, an AI-powered clinical data transformation platform that ingests unstructured patient notes from electronic health records (EHRs) and converts them into structured, de-identified, standardized datasets ready for research, analytics, and clinical trials. The platform bundles privacy-preserving de-identification, clinical NLP coding to ICD-10/SNOMED/RxNorm/LOINC, knowledge graph construction, and a conversational AI copilot, sold to healthcare providers, CROs, pharmaceutical/life sciences companies, and insurance payers.

Is Miimansa a public or private company?

Miimansa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Miimansa founded?

Miimansa was founded in 2023. It employs 11 to 50 people.

How does Miimansa make money?

Three revenue lines are on record. MedBridgeAI SaaS Subscription is the primary driver. The others are bridgeCloud™ Platform Services and trialBridgeAI (Under Development).

Who are Miimansa's main competitors?

Direct peers on record are Deep 6 AI, John Snow Labs, Flatiron Health, TriNetX and Datavant. Broad incumbents are AWS Comprehend Medical, IQVIA, Google Cloud Healthcare API and Microsoft Cloud for Healthcare. Mendel AI is listed as an emerging player.

Does Miimansa have an API?

No public API is recorded for Miimansa.

What industry is Miimansa in?

Miimansa's product category is Healthcare AI Software. Its primary akta.pro industry code is HLACABAJ, Terminology Services & Semantic Interoperability (SNOMED/LOINC/RxNorm mapping), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 513210 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaEmmes, Miimansa AI Partner on Generative AI in Clinical ResearchEmmes Group and Miimansa AI signed a multi-year partnership to integrate Miimansa's Clinical Entity Modeling tools into Emmes' Veridix AI platform. The collaboration aims to automate text processing for clinical research, including protocol authoring and medical writing, to reduce manual data handling costs. The partnership will accelerate Emmes' Gen AI platform, Concord, for faster clinical trials.The Daily RecordEmmes Group partners with Miimansa AI to accelerate adoption of generative AI in clinical researchEmmes Group announced a multi-year partnership with Miimansa AI to acquire its Clinical Entity Modeling tools based on large language modeling and generative AI. The collaboration aims to accelerate automated text processing for clinical research, including protocol authoring and medical writing, to reduce manual data handling costs.PR NewswireEmmes Group kooperiert mit Miimansa AI, um den Einsatz von generativer KI in der klinischen Forschung zu beschleunigenDie Emmes Group, ein globales Auftragsforschungsinstitut mit Sitz in Maryland, gab am 23. Juli 2024 eine mehrjährige strategische Partnerschaft mit dem KI-Startup Miimansa AI bekannt. Im Rahmen der Partnerschaft erwirbt Emmes die Clinical Entity Modeling Tools von Miimansa, die auf Large Language Modeling und generativer KI basieren, um seine Veridix AI-Plattform und die Concord GenAI-Plattform zu erweitern. Ziel ist es, die Verarbeitung klinischer Daten zu beschleunigen und den Zeit- und Kostenaufwand manueller Datenverarbeitung in der klinischen Forschung zu reduzieren.PR NewswireEmmes Group se une a Miimansa AI para acelerar la adopción de la IA generativa en la investigación clínicaEmmes Group, a global technology-driven contract research organization (CRO), announced a multi-year strategic partnership with Miimansa AI involving the acquisition of Miimansa's clinical entity modeling tools based on large language models and generative AI. The partnership aims to accelerate the development of Emmes Group's Concord Gen AI platform and enhance its Veridix AI technology for automated text processing, protocol creation, and medical writing in clinical research. The deal enables Miimansa AI to apply its advanced AI techniques to real-world clinical trial environments, with the goal of making clinical research faster, more affordable, and more efficient.PR NewswireEmmes Group spolupracuje s Miimansa AI s cieľom urýchliť prijatie generatívnej umelej inteligencie v klinickom výskumeEmmes Group has entered a multi-year strategic partnership with Miimansa AI to integrate generative artificial intelligence into clinical research. The collaboration aims to accelerate the development of Emmes' Veridix AI platform by leveraging Miimansa's large language model technology for automated processing of clinical data and documentation.